PIF’s Lifera signs MoU with Sanofi, Arabio to localize vaccine industry

Logo of Pharmaceutical Investment Company (Lifera)

Pharmaceutical Investment Company (Lifera), wholly-owned by the Public Investment Fund (PIF), signed today, July 6, a memorandum of understanding (MoU) with global vaccine maker Sanofi and Arab Company for Pharmaceutical Products (Arabio) to promote the local manufacturing of vaccines in the Kingdom.

According to a Lifera statement, the three parties will explore cooperation opportunities to enhance the localization of the vaccine industry in Saudi Arabia.

They will launch a bundle of initiatives, as the contract between Sanofi and Lifera will enable the former to utilize Lifera’s facilities and its advanced capabilities to manufacture high-quality pharmaceutical products.

Lifera will benefit from Arabio and Tamer Group’s capabilities at the local and regional levels in distributing vaccines and other major pharmaceutical products.

The MoU reflects Lifera’s strategic objectives, aimed at enhancing the flexibility level and the vital industries sector in the Kingdom.

Lifera targets to enable the transfer of knowledge and technical expertise as well as qualifying calibres in the field of vital industries.

This will, in turn, contribute to achieving the Kingdom’s Vision 2030 goals.

According to data compiled by Argaam, last month, PIF announced the establishment of Lifera, a commercial-scale contract development and manufacturing organization.

Lifera intends to focus on manufacturing life-saving and essential pharmaceutical products, including insulins, vaccines, plasma therapeutics, monoclonal antibodies, cell and gene therapies, and innovative small molecules.